Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Jia-You Fang

Jia-You Fang

Chang Gung University, Taiwan

Title: Anti-MRSA activity of cationic lipid carriers in combination with oxacillin for eradicating skin infection

Biography

Biography: Jia-You Fang

Abstract

Nanoparticles have been the focus of being the antibacterial agents. The aim of this study was to evaluate the anti-methicillin-resistant Staphylococcus aureus(MRSA) activity of cationic nanostructured lipid carriers (NLC) combined with oxacillin against ATCC 33591 and clinical isolate. The cationic resource on NLC surface was the decoration of soyaethyl morpholinium ethosulfate (SME). NLC loaded with oxacillin was produced to assess antibacterial activity and the topical application for treating cutaneous infection. The hydrodynamic diameter and zeta potential of oxacillin-loaded NLC were 177 nm and 19 mV, respectively. Oxacillin exhibited synergistic MRSA eradication when combined with NLC. The minimum bactericidal concentration (MBC) of oxacillin was decreased from 250 to 62.5 μg/ml after NLC encapsulation. The combined NLC and oxacillin reduced MRSA biofilm thickness from 31.2 to 13.0 μm, which was less than NLC (18.2 μm) and antibiotic (25.2 μm) alone. The oxacillin-loaded NLC showed a significant reduction in the burden of intracellular MRSA in differentiated THP-1 cells. This reduction was greater than that of individual treatment. The mechanistic study demonstrated the ability of cationic NLC to disrupt bacterial membrane, leading to the protein leakage. The cell surface disintegration also increased oxacillin delivery into the cytoplasm for activating the bactericidal process. Topical NLC treatment of MRSA abscess in skin decreased bacterial load by 4 logarithm and improved skin architecture and barrier function. Our results demonstrated that a combination of nanocarriers and an antibiotic could synergistically inhibit MRSA growth. It can be a potential approach to resolve the risk of drug resistance.